Pierre Beaurang - Aug 10, 2021 Form 4 Insider Report for Nurix Therapeutics, Inc. (NRIX)

Role
Chief Business Officer
Signature
/s/ Christine Ring, as Attorney-in-Fact for Pierre Beaurang
Stock symbol
NRIX
Transactions as of
Aug 10, 2021
Transactions value $
-$215,601
Form type
4
Date filed
8/11/2021, 06:20 PM
Previous filing
Jul 12, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NRIX Common Stock Options Exercise $8.33K +7.5K +173.21% $1.11* 11.8K Aug 10, 2021 Direct F1
transaction NRIX Common Stock Sale -$167K -5.62K -47.51% $29.74 6.21K Aug 10, 2021 Direct F1, F2
transaction NRIX Common Stock Sale -$56.8K -1.88K -30.27% $30.21 4.33K Aug 10, 2021 Direct F1, F3
holding NRIX Common Stock 117K Aug 10, 2021 By Trust F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NRIX Employee Stock Option (right to buy) Options Exercise $0 -7.5K -53.34% $0.00 6.56K Aug 10, 2021 Common Stock 7.5K $1.11 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
F2 Represents the weighted average sale price. The lowest price at which shares were sold was $29.07 and the highest price at which shares were sold was $30.06. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
F3 Represents the weighted average sale price. The lowest price at which shares were sold was $30.07 and the highest price at which shares were sold was $30.34.
F4 The Reporting Person is a trustee of the Beaurang-Sligh Family Trust. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
F5 The option is fully vested.